5. Gilead’s got cash to spend

Gilead, the once-tiny biotech that made headlines with its Hep C blockbuster, told Bloomberg that it’s looking to “do important deals.”  CEO John Milligan said that the company has $21.3 billion in cash and Gilead is looking to expand its oncology platform with a drug they can “rally around.” TBD on whether Milligan can repeat the success of his predecessor, whose $11 billion acquisition of Pharmasset and its hepatitis C drug, Solvaldi, doubled Gilead’s revenue. Milligan’s announcement comes after sales of Gilead’s two Hep C pills, among the fastest-selling drugs of all time, fell for the first time last quarter.